Harvard Bioscience Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

John Duke

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

Further Upside For Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Could Introduce Price Risks After 27% Bounce

Dec 04

Harvard Bioscience, Inc. (NASDAQ:HBIO) Looks Inexpensive But Perhaps Not Attractive Enough

Oct 20

Harvard Bioscience, Inc. (NASDAQ:HBIO) Just Reported, And Analysts Assigned A US$3.00 Price Target

Aug 14

Does Harvard Bioscience (NASDAQ:HBIO) Have A Healthy Balance Sheet?

Jul 23

Little Excitement Around Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Revenues As Shares Take 26% Pounding

May 29

Expanding SoHo, BTX, And Mesh MEA Will Open New Markets

May 15 Expansion of SoHo platform and BTX systems could drive revenue growth in industrial and academic markets through broader applications and bioproduction processes.

Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?

May 02

Lacklustre Performance Is Driving Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 49% Price Drop

Apr 11

Harvard Bioscience, Inc. (NASDAQ:HBIO) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough

Feb 07

Why Investors Shouldn't Be Surprised By Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 31% Share Price Plunge

Feb 07

Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Dec 22

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

Sep 23

Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 10

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Apr 26

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

Apr 11

Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M

Aug 04

Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

Jun 08

Harvard Bioscience - Dressed Up And Waiting For A Suitor

Mar 15

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Feb 16

CEO

John Duke (54 yo)

less than a year

Tenure

Mr. John Duke is Director of Harvard Bioscience, Inc. from June 2, 2025 and its President and CEO since July 28, 2025. Mr. Duke serves as Chief Executive Officer of Plastic Molding Technology. Prior to joi...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
John Duke	President	less than a year	geen gegevens	geen gegevens
Mark Frost	Interim CFO	less than a year	geen gegevens	0.056% $ 18.1k
Ryan Wallace	Senior Vice President of Global Sales	2.6yrs	geen gegevens	geen gegevens
Lori Packer	Vice President of Global People Operations	no data	geen gegevens	geen gegevens
Kathryn Flynn	Corporate Controller	no data	geen gegevens	geen gegevens
David Sirois	Director of Corporate Accounting & SEC Reporting	no data	geen gegevens	geen gegevens

0.6yrs

Gemiddelde duur

Ervaren management: Het managementteam van HBIO wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.6 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
John Duke	President	less than a year	geen gegevens	geen gegevens
William Snider	Director	no data	geen gegevens	geen gegevens
Stephen DeNelsky	Director	less than a year	geen gegevens	geen gegevens
Robert Gagnon	Director	less than a year	US$719.77k	geen gegevens
Seth Benson	Director	less than a year	geen gegevens	geen gegevens
Katherine Eade	Lead Independent Director	8.2yrs	US$223.00k	0.70% $ 225.7k

0.4yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van HBIO wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.4 jaar), wat duidt op een nieuw bestuur.

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/12/26 05:22
Aandelenkoers aan het einde van de dag	2025/12/26 00:00
Inkomsten	2025/09/30
Jaarlijkse inkomsten	2024/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Harvard Bioscience, Inc. wordt gevolgd door 6 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Raymond Myers	Benchmark Company
Bruce Jackson	Benchmark Company
Paul Knight	Janney Montgomery Scott LLC

Harvard Bioscience Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Harvard Bioscience, Inc. Appoints Stephen Denelsky to Board of Directors and as Member of Nominating & Governance Committee, Effective September 5, 2025

Harvard Bioscience, Inc. Announces Board and Committee Changes

Harvard Bioscience, Inc., Annual General Meeting, Jun 02, 2025

Harvard Bioscience, Inc. Announces Bertrand Loy Not Standing for Re-Election as Lead Independent Director and as Member of the Audit Committee and the Nominating and Governance Committee

Harvard Bioscience, Inc., Annual General Meeting, May 14, 2024

Recent updates

New major risk - Share price stability

Harvard Bioscience, Inc. announced that it expects to receive $40 million in funding from BroadOak Capital Partners, LLC

Further Upside For Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Could Introduce Price Risks After 27% Bounce

Harvard Bioscience, Inc. Provides Earnings Guidance for the Fourth Quarter of 2025

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Harvard Bioscience, Inc. to Report Q3, 2025 Results on Nov 06, 2025

Harvard Bioscience, Inc. (NASDAQ:HBIO) Looks Inexpensive But Perhaps Not Attractive Enough

Price target decreased by 33% to US$2.00

Less than half of directors are independent

Harvard Bioscience Receives a Notification Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Harvard Bioscience, Inc. Appoints Stephen Denelsky to Board of Directors and as Member of Nominating & Governance Committee, Effective September 5, 2025

Harvard Bioscience, Inc. (NASDAQ:HBIO) Just Reported, And Analysts Assigned A US$3.00 Price Target

Harvard Bioscience, Inc. Provides Earnings Guidance for the Third Quarter Ending September 30, 2025

Does Harvard Bioscience (NASDAQ:HBIO) Have A Healthy Balance Sheet?

Harvard Bioscience, Inc. to Report Q2, 2025 Results on Aug 11, 2025

Harvard Bioscience, Inc. Provides Non-Compliance Update

Harvard Bioscience Receives Nasdaq Non-Compliance Notice Regarding Audit Committee Requirement

Harvard Bioscience, Inc. Announces Board and Committee Changes

Little Excitement Around Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Revenues As Shares Take 26% Pounding

Expanding SoHo, BTX, And Mesh MEA Will Open New Markets

Harvard Bioscience, Inc. Reports Impairment for First Quarter of 2025

Harvard Bioscience, Inc. to Report Q1, 2025 Results on May 12, 2025

Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?

Harvard Bioscience, Inc., Annual General Meeting, Jun 02, 2025

Harvard Bioscience, Inc. Announces Bertrand Loy Not Standing for Re-Election as Lead Independent Director and as Member of the Audit Committee and the Nominating and Governance Committee

Harvard Bioscience Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Lacklustre Performance Is Driving Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 49% Price Drop

Harvard Bioscience, Inc. Provides Earnings Guidance for the First Quarter of 2025

Harvard Bioscience, Inc. to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting

Harvard Bioscience, Inc. (NASDAQ:HBIO) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough

Why Investors Shouldn't Be Surprised By Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 31% Share Price Plunge

Harvard Bioscience, Inc. Provides Revenue Guidance for the Fourth Quarter of 2024

Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?

Harvard Bioscience, Inc. to Showcase Innovative Technologies at Society for Neuroscience Annual Meeting 2024

Harvard Bioscience, Inc. to Showcase Latest Solutions for Preclinical and Organoid Applications At Safety Pharmacology Society Annual Meeting

Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2024

Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Harvard Bioscience, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story

Harvard Bioscience, Inc. Provides Earnings Guidance for the Full Year 2024

Harvard Bioscience, Inc. to Report Q1, 2024 Results on May 07, 2024

Harvard Bioscience, Inc. Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth

Harvard Bioscience, Inc., Annual General Meeting, May 14, 2024

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS misses analyst expectations

Harvard Bioscience, Inc. Provides Revenue Guidance for the Full Year 2024

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications At Society of Toxicology Meeting

Harvard Bioscience, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2023

Harvard Bioscience, Inc. to Showcase Latest Innovations in Preclinical and Organoid Research At Society for Neuroscience Conference

Harvard Bioscience, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

President recently bought US$110k worth of stock

Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

New minor risk - Shareholder dilution

Harvard Bioscience, Inc. Provides Earnings Guidance for Full Year 2023

Now 22% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Harvard Bioscience, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Now 20% undervalued

Harvard Bioscience, Inc. Appoints Jennifer Cote as Chief Financial Officer

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

President recently bought US$105k worth of stock

Forecast breakeven date moved forward to 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

President recently bought US$75k worth of stock